Nils Lonberg

Three decades of experience in the biotech and pharma industries focused on platform innovation, drug discovery, and drug development. Nils Lonberg a leader in the use of genetically engineered mice for antibody drug discovery, resulting in multiple FDA-approved antibody products; conducted substantial research involving transgenic mice in order to discover new medicines that could be effective for humans. Currently an Executive in Residence at Canaan Partners, an early-stage venture capital firm; previously served as Senior Vice President of Biologics Discovery and led oncology discovery at Bristol-Myers Squibb. Nils holds a Ph.D. in Biochemistry and Molecular Biology from Harvard University.